Abstract

Actin cytoskeleton is well-known for providing structural/mechanical support, but whether and how it regulates chromatin and cell fate reprogramming is far less clear. Here, we report that MKL1, the key transcriptional co-activator of many actin cytoskeletal genes, regulates genomic accessibility and cell fate reprogramming. The MKL1-actin pathway weakens during somatic cell reprogramming by pluripotency transcription factors. Cells that reprogram efficiently display low endogenous MKL1 and inhibition of actin polymerization promotes mature pluripotency activation. Sustained MKL1 expression at a level seen in typical fibroblasts yields excessive actin cytoskeleton, decreases nuclear volume and reduces global chromatin accessibility, stalling cells on their trajectory toward mature pluripotency. In addition, the MKL1-actin imposed block of pluripotency can be bypassed, at least partially, when the Sun2-containing linker of the nucleoskeleton and cytoskeleton (LINC) complex is inhibited. Thus, we unveil a previously unappreciated aspect of control on chromatin and cell fate reprogramming exerted by the MKL1-actin pathway.

MKL1 is a key transcriptional co-activator of actin cytoskeleton genes. Here the authors show that MKL1 activation in somatic cells reduces chromatin accessibility and hinders full reprogramming to pluripotency. Reduction of MKL1, disruption of actin cytoskeleton and its links to the nucleus relieve this repression.

Details

Title
MKL1-actin pathway restricts chromatin accessibility and prevents mature pluripotency activation
Author
Hu, Xiao 1 ; Liu, Zongzhi Z 2 ; Chen Xinyue 1 ; Schulz, Vincent P 3 ; Kumar, Abhishek 4   VIAFID ORCID Logo  ; Hartman, Amaleah A 1 ; Weinstein, Jason 1 ; Johnston, Jessica F 5   VIAFID ORCID Logo  ; Rodriguez, Elisa C 5 ; Eastman, Anna E 1 ; Cheng, Jijun 6 ; Min, Liz 5 ; Zhong Mei 1 ; Carroll, Christopher 5 ; Gallagher, Patrick G 7 ; Lu, Jun 6 ; Schwartz, Martin 4   VIAFID ORCID Logo  ; King, Megan C 5 ; Krause, Diane S 8 ; Guo Shangqin 1 

 Yale University, Department of Cell Biology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Yale Stem Cell Center, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University, Department of Cell Biology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Yale Stem Cell Center, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Department of Pathology, Yale Cancer Center, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University, Department of Pediatrics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University, Department of Medicine (Cardiology), New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University, Department of Cell Biology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University, Yale Stem Cell Center, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Department of Genetics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University, Department of Pathology, Yale Cancer Center, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Department of Pediatrics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Department of Genetics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Yale University, Department of Cell Biology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Yale Stem Cell Center, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Department of Laboratory Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2208721668
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.